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Abstract. My professional research career spanning more than four decades has been largely devoted to 
synthetic medicinal chemistry (Ciba, Bombay – now Mumbai – 21 years) followed by an equal number 
of years in process development of drugs, crop protection chemicals (Searle, Bombay) and drugs and 
speciality chemicals (Recon and Hikal, Bangalore). These efforts have involved several collaborators in-
cluding many from other institutions and offered multitudinous challenges calling for continuous creativ-
ity in industrial setups. I was fortunate to have had a conducive environment to be able to respond to 
these challenges. I attempt to offer the readers in the ensuing pages a flavour of the excitement that has 
marked these years. 
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1. Introduction 
I started my professional career in January 1963 at 
the Ciba Research Centre in Goregaon of suburban 
Bombay when I returned to India after a year’s post-
doctoral work (1961– 2) with Prof H Schmid at Zu-
rich University on strychnine1 and the Kopsia alka-
loids,2,3 followed by practical training for 4 months 
at the Ciba laboratories in Basel. Earlier I had done 
my PhD with Prof T R Govindachari at Presidency 
College, Madras (1950–54) and contiued with him 
in the same field as a research fellow in a CSIR 
scheme (1954–57). This work included structu al 
elucidation of the alkaloids tylophorine4 and gentia-
nine,5 and the oxygen heterocycle, wedelolactone,6 
besides synthesis of aporphines7,8 and benzylisoqui-
nolines9 and benzophenanthridines.10 Subsequently, I 
postdoctored with Prof C L Stevens at Wayne State 
University, Detroit in the area of aminosugar nucleo-
sides11,12 and with Prof J D Roberts at the California 
Institute of Technology, Pasadena in cyclobutadiene 
chemistry13 and the then-emerging area of nuclear 
magnetic resonance spectroscopy (NMR).14,15 
2. Ciba Research Centre, Bombay (now Mumbai) 
The Centre started functioning from January 1963 
under the direction of Prof T R Govindachari and 
was f rmally inaugurated by Pandit Jawaharlal Nehru 
later in March. It was devoted to the discov ry of 
new drugs. It had in place the required interdiscipli-
nary team of chemists, biologists, biochemists, toxi-
cologists and clinical investigators and was uniquely 
well equipped with contemporary instrumentation 
required by the various disciplines for carrying out 
research to international standards. The research 
centre had a beautiful sprawling campus with aes-
thetically built laboratories and residential quarters 
which provided an exhilarating atmosphere suppor-
tive of creative and productive research. By June 
1984 when the author moved to Searle, India to take 
up the leadership of their R&D Centre, about 18,000 
preparations, most of them new synthetic compounds 
and the rest, plant-derived extracts or single entities 
had been screened using a variety of biological pa-
rameters for effects on the cardiovascular, central 
nervous and endocrine systems and in infectious 
diseases due to bacteria, amoeba and helminths. 
Promising compounds which had passed through 
advanced biology and toxicol gy were taken to the 
clinic, of which five survived Phase I, II and III 
cli ical trials in humans and were afforded registra-
tion by the Drug Controller of India.
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3. Drug discovery research, then and now 
The process of new drug development in those days 
was largely driven by chemistry and involved syn-
thesis of new compounds based upon analogy to ex-
isting drugs of synthetic or natural origin or simple 
biochemical concepts. It was aided by random 
screening of novel chemical types and serendipity 
(as it is even now and will always be). Compounds 
were synthesized one at a time; a productive chemist 
with a couple of associates on the average submitted 
10–20 compounds per month. Plants were extracted 
and examined systematically. There were not many 
‘rational’ approaches available to optimize leads but 
as the years passed by, methods such as quantitative 
structure–activity relationships evolved and were 
exploited. Compounds were mostly screened di ctly 
in animal models rather than against biological tar-
gets. There were relatively few in vitro tests to help 
scientists anticipate activity. This was also the case 
with amoebic and helminthic infections but micro-
biology was aided more by in vitro tests prior to in 
vivo studies. After activity was obtained and opti-
mized, mechanistic studies were carried out to the 
extent that science had progressed. Compounds cho-
sen for further development underwent full biological 
characterization, ADME (absorption, drug metabo-
lism, excretion) and toxicology studies of various 
durations and kinds. With the results of these studies 
and appropriate formulations, the candidate drugs 
would undergo clinical trials and the successful on  
would eventually get marketing permission.  
 Dramatic changes have taken place since the 
1980s in the discovery search for new drugs. Revo-
lution in molecular biology, the unraveling of several 
genomes and the arrival of micro array technology 
have made possible the isolation and expression of 
several proteins – enzymes and receptors that are 
relevant to various disease conditions. Binding/ 
inhibition by test compounds offers a rational ap-
proach as a first step towards finding drugs for these 
diseases. The development of high throughput 
screening (HTS) has made this process very rapid. 
To engage the unbottled genie fully, increasingly 
larger numbers of compounds are required. Chemists 
have risen to the occasion by providing vast lbraries 
of compounds using combinatorial/parallel chemis-
try. Unlike the earlier days, since HTS is done in vi-
tro, only milligram quantities of the test compounds 
are needed. With the right chemistry and instrumen-
tation in place, a chemist with a couple of associates 
can easily churn out hundreds of compounds in a 
month. It is not unusual now for discovery-based 
MNC Pharma companies to have libraries of 100,000 
compounds or more. Hits thrown up by such screen-
ing of random libraries are studied for binding 
strengths or inhibitory concentratio s and optimized 
using well-established parameters. A notable depar-
ture from the practice prior to 1980 is that the DMPK 
(drug metabolism; pharmacokinetics) characteristics 
of i portant lead compounds are studied at this 
s age to ensure proper bioavailability/protein bind-
ing properties for representative compounds of the 
chemical class when exposed to in vivosituations. 
The compounds progress only then to time-c nsu-
ming and expensive in vivo animal studies. The pro-
ject enters lead optimization stage at this point 
wherein the medicinal chemist utilizes principles 
th t re well established and accepted for synthesiz-
ing ‘druglike’ or ‘druggable’ molecules. One favour-
it concept relates to Lipinski’s ‘rule of five’ 
consisting of four important and desirable proper-
ties – molecular mass <500, calculated log P (parti-
tion coefficient of the test compound between 
octanol and water) <5, hydrogen bond donors <5 
and hydrogen bond acceptors <10. More advanced 
approaches to optimization involve X-ray crystal 
structures of proteins without and with ligands 
which provide sophisticated methods of docking pu-
tative drugs for maximal desired interactions. High-
field NMR has been marshalled to investigate the 
more meaningful interactions in biological milieus. 
 The lead-optimized compound would then be cha-
racterizd extensively biologically and some under-
standing of its mechanism of action arrived at. 
Further development through drug metabolism, toxi-
cology and clinical studies follows essentially the 
earlier route except there is a serious move now to 
use biomarkers to follow clinical trials rather than 
disease end points. During recent years, emphasis 
h s been generally on finding molecules that would 
have a single target in a disease but this is being in-
creasingly questioned vociferously. ‘The idea of 
magic bullets is great but in practice it is probably 
not going to be the right approach for complex dis-
eases.’ There has been also widespread concern over 
the declining trend in new drug introductions despite 
t  enormous resources of knowledge, technology, 
instrumentation and money invested by Pharma 
c mpanies leading inevitably to skeptics making 
snide remarks over the so-called ‘rational’ appro-
aches. 
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 Medicinal chemists have always played a pivotal 
role in the discovery and development of new drugs. 
In the light of current challenges, several skills are 
required for the medicinal chemist. These have been 
outlined in an excellent article by Lombardino and 
Lowe III in a recent article in Nature Reviews.16 I 
can do no better than quote: 
 
“These (the skills) include a thorough knowledge of 
modern organic chemistry and medicinal chemistry, 
an understanding of the biology that relates to the 
target disease, an understanding of the pharmacolo-
gical tests used in the project and sufficient knowl dge 
of the factors that influence ADME characteristics 
of chemicals in vivo. Furthermore, they should also 
have an understanding of clinical medicine that per-
tains to the target disease; knowledge of the regulatory 
requirements for related drugs, a current knowledge 
of competitive therapies, both in the market and un-
der development by competitors; a thorough knowl-
edge of the literature that is relevant to the target 
disease; familiarity with the many newer technolo-
gies available to facilitate drug discovery; and an 
entrepreneurial attitude in behaving as an innovator 
and inventor. Finally – and of crucial importance to 
the timely success of the proj ct – the chemist must 
show superior interpersonal skills throughout the 
life of the project to interact effectively with col-
leagues from other disciplines to achieve proj ct 
goals.” 
 The author will now proceed to give a brief account 
of important results from his foray into medicinal 
chemistry as it was practised th n (1963–1984).  
4. Contributions to medicinal chemistry 
4.1 Antidepressant activity – Sintamil 
The synthesis of the antidepressant, sintamil 5 
(scheme 1) exploited the double activation of the 
chlorine atom in the readily available 2-chloro-5-
nitrobenzoic acid. The acid chloride 1 acylates 
selectively the amine in 2-aminophenol 2 to yield 
the amide 3. This undergoes facile intramolecular 
cyclization by merely heating its solution in aqueous 
alkali to afford the dibenzoxa epinone 4 in very high 
yield, offering easy access to the tricyclic system which 
requires otherwise several steps and unfriendly re-
agents. Antidepressant activity is expected to be 
elicited from 4 by introducing an aminoalkyl side 
chain on the lactam nitrogen and is achieved, again, 
under surprisingly mild conditi s by treating 4 with 
aminoalkyl chloride hydrochlorides in aqueous al-
kali– c tone solution.17 Aminoalkylation of lactams 
g nerally require dry, aprotic solvents, sodium hy-
dride or amide and the none-too-stable aminoalkyl 
halide bases. The products have the expected anti-
depressant activity, the dimethyaminopropyl driva-
tive, sintamil 5 (code No. Go 2330) being the most 
pot nt17. Sintamil is found to be superior to imipra-
mine, the standard antidepressant at that time in sele-
cted parameters.18 14C-labelled drug was synthesized 
f r absorption–excretion studies.19 Sintamil was 
granted marketing permission by the Drug Control-
ler of India and Ciba launched it after an introduc-
tory ymposium in 1972.20 The actual marketing 
owever took place some years later due to the p-
culiar restrictive licensing policies of the Central 
Government at that time. 
An interesting and beneficial fallout of having the 
nitro group was the patentability of 5. Earlier patents 
on the dibenzoxazepine system had not covered the 
nitro substituent since the synthetic routes precluded 
the use of this group! Many tri- and tetracyclic 
molecules produced in this project have varied acti-
vity on the central nervous system.17,21 Interestingly, 
years later some are found to have even anti HIV ac-
tivity, particularly the tetracyclic analogues of 422!  
 Among various studies carried out on 5 can be 
mentioned the determination of structure and con-
formation in the solid state23 nd in solution24 in col-
laboration with Profs K Venkatesan and G Govil 
respectively. 
 Several fascinating transformations were encoun-
tered in this chemistry. The formation of the benzo-
xazole 7 along with the expected iminochloride 6 
from 4 by the action of POCl3 in the presence of dime-
thylaniline is one illustrative example (scheme 2).25 
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 In a different exercise involving the replacement 
of an active chlorine in a-alpha-chlorodiphenyl-
acetamides, a novel observation was made of the 
unusual entrance of the nucleophile at the position 
para to the side chain.26 
4.2 Nasal decongestant – Tinazoline 
Tinazoline 11 (code No. Go 7996 B), a vasocon-
strictor useful as a nasal decongestant, was synthe-
sized, based upon the pharmacological activity of 
imidazolines and the facile introduction of an 
isothiourea moiety in the beta position of indoles by 
thiourea in the presence of potassium triiodide. Thus 
indoles 8 and cyclic and acyclic thioureas 9 undergo 
oxidative coupling to afford 3-in olyl mercapto de-
rivatives 1027 among which tinazoline 11 derived 
from indole and imidazolinethione (scheme 3), is the
most potent vasoconstrictor,28 and was given mar-
keting permission in India. Although 11 had some 
advantages over the classical Ciba drug, xylometa-
zoline (otrivin), the company chose not to market it 
lest it should cannabilize the sales of the latter. The 
chemistry afforded the interesting tetracyclic system 
1227 which was inactive in this indication. 12 was 
not tested for tumor-inhibiting properties. 
4.3 Antiamoebic activity – Satranidazole 
Following the world-wide merger of Ciba and Geigy 
in the early seventies, the development of an anti-
microbial agent active against both luminal and hep tic 
amoebiasis became a high priority for the Goregaon 
Research Centre. A promising nitroimidazole lead 
discovered in the Basel laboraotories was also tran-
ferred to Goregaon. The project taken up on a war 
footing culminated in the development of a new ana-
logue, satranidazole 18 (Code No. Go 10213). The 
synthetic sequenc  started with 1-methyl-2-merca-
ptoimidazole 13which was S-methylated to 14. This 
was then nitrated to 15 and oxidized to the sulphone 
16. Reaction of 16 with the sodium salt of 1-metha-
nesulphonylimidazolidinone 17 gave satranidazole 
18 in high yield (scheme 4).29–31 The compounds 
significantly superior to the standard drug, metroni-
dazole in caecal and hepatic amoebi sis,32 giardiasis 
and trichomoniasis.33 The superiority extends to ac-
tivity against anaerobic bacteria also. Methanesul-
phonyl residue was introduced in 17 as a blocking 
group with a view to knocking it off in 18 and re-
placing it with an acetyl group, which was the initial 
l ad. In the event, it turns out that 18 is unwilling to 
part with the methanesulphonyl group but is more 
potent and is obtained in higher yields with less has-
sles than the initial acetyl anlogue! Blocking groups 
have apparently better roles to play! 18 underwent 
the entire gamut of new drug development, which 
among other activities requi ed the synthesis of 14C-
labelled drugs34,35 and was projected in an interna-
tional seminar.36 Ciba (by then Ciba-Geigy) obtai-
ned marketing permission for 18 from the Drug 
Controller of India but abstained from int ducing it 
for some reasons. It was left to Alkem Laboratories 
to make it available to the public in 2000,37 long after 
the original patents had expired. The author’s exten-
sive work on satranidazole-related chemistry un-
veiled several interesting reactions, one of which is 
outlined below. 
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 An attempt to methylate the sulphonamide nitrogen 
atom in 19 with excess diazomethane gave a plethor  
of products, which were isolated by painstaking 
chromatography and identified as 20–24. Methyla-
tion of the nuclear nitrogen in 19 followed by cyclo-
addition of diazomethane to the nitrovinyl moiety 
and elimination of nitrite affords an imidzopyrazole 
which undergoes further methylation at the pyrzole 
nitrogen sites to form 21 and 22 or is attacked by 
adventitious methyl isocyanate present in diazome-
thane to afford the carb moyl derivatives 23 and 24 
(scheme 5).38,39 
4.4 Antiamoebic activity – Quinfamide 
Diloxanide furoate 25 has been all along a useful 
luminal amoebicide. During our exercises to develop 
amoebicides, a cyclic analogue 27 was synthesized 
sta ting from 6-hydroxy-1,2,3,4-tetrahydroquinoline 
26 in two obvious steps (scheme 6). 27 like 25 does 
not exhibit antiamoebic activity in the caecal model. 
The hamster model, more relevant for luminal 
amoebiasis, was unavailable to us at that time. 27 
was considered by Ciba to be of no interest. Subse-
quently, Sterling–Winthrop established its potency 
and superiority to 25 in the latter model and pat-
ented it as quinfamide. Searle India got interested in 
the drug and manufactured it for export. My col-
league, Sharada Shenoy, and I developed the process 
for the drug in the Searle laboratories and obtained 
an Indian patent. 
4.5 Antitubercular activity – CGI 17341 
An unexpected offshoot of my protracted engag-
ment in nitroimidazole chemistry was the synthesis 
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of CGI 17341 (30) with potent antitubercular acti-
vity.40 This has come to be regarded as an important 
lead in a therapeutic area where there was a crying 
need for new drugs (more so for HIV-associated TB) 
but which was bereft of breakthroughs since the 
days of rifampicin, isoniazid, ethambutol and pyra-
zinamide. 30 is synthesized from 2,4-dinitro-
imidazole 28, which upon treatment with butylene 
oxide gives a mixture of the alcohol 29 and the im-
dazooxazole 30 along with isomeric nitro com-
pounds. Exposure of 29 to piperidine gives a further 
amount of 30 (scheme 7). 30has good anti TB activity 
in vitro against sensitive and resistant TB strains and 
is also active in vivo. The in vitro and in vivo effica-
cies compare well with those f rifampicin and 
isoniazid. In the absence of a planned effort to ex-
ploit the lead, I was allowed to publish the results; 
further elaborate characterization of the activi y and 
presentation in an international conference and a 
leading journal41 brought he molecule widespread 
attention. Sure enough, the lead was picked up by 
two different laboratories resulting in the develop-
ment of two potent analogues, the nitroimidazooxa-
zole 31 and the nitroimidazooxazine 32, which have 
entered phase I clinical trials. It is a matter of eternal 
regret to me that Ciba did not deem it worthwhile to 
continue with the CGI 17341 project. However, the 
opening of a research centre by Novartis in Singa-
pore devoted to discovery of new anti TB drugs re-
cently is an encouraging development! If either 31
or 32 or both succeed in the clinic, scientists of the 
Goregaon Research Centre can feel fulfill d. 
4.6 Antifertility activi y 
For several years since its inception, the Goregaon 
Research Centre had a strong and sustained pro-
gramme to develop synthetic antifertility agents 
which could hopefully address the population problem 
of India. Several interesting and potent leads were 
obtained but none reached the clinic.  
 
Go 2696: Investigation of a series of 1-aryl-
thiosemicarbazides revealed strong antifertility acti-
vity for 33 (X = S) which acts by virtue of its antiu-
terotropic activity but was abandoned because of its 
toxicity and teratogenic properties.42,43 Undaunted, 
the involved scientists were valiantly talking for 
some time ofits potential use as a rodenticide-cum-
rodent population control agent! Interestingly, the 
corresponding semicarbazide (GO3165, 33 X = O) 
is a powerful anticonvulsant.44 This class of com-
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pounds offered an opportunity for testing the utility 
of the concept of quantitative structure activity rela-
tionships (QSAR) which was becoming quite poplar 
at that time. My colleague, Dr Rajappa, had developed 
great fascination for the subject and undertook the 
analysis with great avidity. 
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Go 5380: 1,2-Diaryldihydronaphthalenes were be-
ing studied seriously in the late fifties and early sixti s 
as antiimplantation agents. This inspired the synthesis 
of 1,2-diaryltetrahydroisoquinolines 37 by a classi-
cal route from 34via 35 and 36 (scheme 8). Among 
these, fluorine-substituted derivatives have signifi-
cant activity. The p-fluorophenyl derivat e 38 (Go 
5380) is the most potent and has been studied in de ail, 
and its activity attributed to its weak estrogenic–
antiestrogenic properties.45 Later this was not consi-
dered a promising mechanism for antifertility activity  
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Scheme 8. 
and 38 was not pursued although centchroman 39 of 
Central Drug Research Institute, a contemporary 
molecule with similar structure and properties was 
d veloped and introduced in the market. However, 
m re than three decades later, 38 and analogues 
have been found to be attractive canddates for Prof 
T N Guru Row’s investigations on intermolecular F–F 
interactions in organic compounds in the solid state 
(vide infra)! 
 Several other 1,2-diaryl heterocycles were synthe-
sized by me during those years which are discusse  
in the next section on enamine chemistry. 
5. Enamine chemistry 
The versatile applications of enamines as synthons 
are well documented. I have had an enduringinterest 
in the theoretical studies of enamine characteristics 
by NMR studies (vide infra) and their use in co-
structing diverse biologically active condensed pyr-
roles and perhydrocinnolines. These exercises also 
divulged some unexpected reactions. These as w ll 
as some novel properties of imidazoisoquinolnes a d 
1-methyl-3,4-dihydroisoquinolines are discussed in 
this section. 
5.1 Condensed pyrroles and cinnolines 
Reaction of enamines 40 of cycloalkanones with a-
bromoacetophenones 41 give the 1,4-diketones 42, 
which undergo facile ring closure to pyrroles 43 
(scheme 9) when heated with anilines. Among these 
44 has potent antiimplantation properties.46 
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Scheme 9. 
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Cyclohexane-1,3-diones 45 undergo C-alkylation by 
a-haloketones to give triones 46 (R1 = alkyl, aryl) 
which again can be converted by aromatic amines to 
ketotetrahydroindoles of the type 47. 47 has very 
good antiimplantation activity which is surpassed by 
the derived alcohol 48 and even more so by the 
hydrogenolysis product 4946 (scheme 10). They were 
not developed further for the reason mentioned ear-
lier but nevertheless they have become good candi-
dates for Prof Guru Row’s studies. 
 Alkylation of 45 with ethylchloroacetate affords 
46 (R = OEt) which upon heating with anilines gives 
the ketotetrahydrooxindoles 50, which are hydro-
lyzed to the acids 51 (scheme 11). The latter been 
close resemblance to the classical anti-inflammatory 
agent, diclofenac and in fact the molecule 51 
(R = H, Ar = 2,6-dichlorophenyl) should yield dc o-
fenac on dehydrogenation. While this was not real-
ized, 50 and 51 are by themselves antiinfammatory, 
the former being more potent. However, the most 
active oxindole of this series, 50 (R = H, Ar = 4-
fluorophenyl) is much less potent than diclofe ac.47 
 An unexpected novel reaction is encountered 
when triketones 46 (R1 = aryl) are exposed to N,N-
disubstituted hydrazines. Reaction of the 1,4-diketone 
52 with N-aminopiperidine affords the expected pyr-
role 53 whereas a similar one with the triketone 54 
gives the totally unexpected 3-piperidino derivative 
55 (scheme 12) in high yield. The reaction was 
demonstrated to be a general one and its mechanism 
elucidated.48,49 
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 Reaction of triketones of the type 46 (R1 = aryl) 
with hydrazine and monosubstituted hydrazines gives 
perhydrocinnolines 56, among which 57 has some 
CNS depressant properties50 (scheme 13). 
 An attempt to carry out a Beckman transformation 
on the oxime obtained from 56 (R = Me, R1 = H, 
Ar = Ph) with POCl3 took a novel turn to provide the 
fully aromatic aminocinnoline 58 (scheme 13) with 
a methyl shift via a Semmler–Wolff rearrange-
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ment. The reaction is general. Similar products are 
obtained directly from the ketones under Schmidt 
reaction conditions.51,52 Other types of compounds 
which evolved out of this chemistry are summarized 
below. 
 Several 4-oxoperhydroindole-3-acetic acids 60 
derived from 59 (scheme 14) show modest hypogly-
cemic activity among which Go 8778 (R = Me, R1 = 
n-Bu) and Go 9001 (R= Me, R1 = iso-Bu) were 
equipotent with tolbutamide.53,54 Strangely, moving 
the acetic acid si e chain to position 2 as in 62 de-
stroys the activity. However, the series typified by 
65 obtained from dimedone 63 via 64 having a di-
medonyl moiety at position 3 (scheme 14), is highly 
active. The most potent of them, CGI 14600 (65 
R = Ph), exhibits hypoglycemic effects in normal 
fasted rats even at 1×5 mg/kg p.o. nearly matching 
the potency of glibenclamide.55,56 1H NMR and 
mass spectra of CGI 14600 present many interesting 
features. Particularly intriguing is the observati n of 
a major fragment in the latt r indicating the loss of 
CH2CO2H. Insight using the deuterium-labelled 
molecule was obtained by Dr W J Richter.57 
5.2 Imidazoisoquinolines 
Condensation of homophthalic acids 66 with 1,2 and 
1,3-diamines 67 gave a group of imidazo and pyri-
mi oisoquinolones 68 (scheme 15) with an active 
enamine system,58 which gave me much pleasur  
and excitement. 
 One reaction in particular is worth highlighting 
since it afforded a ‘synthetic’ alkaloid and is recor-
ded below. An attempted Mannich reaction of im-
Kuppuswamy Nagarajan 
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dazoisoquinolone 69 with formaldehyde and mor-
pholine gave two products in high yields, neither 
having a morpholine residue. The same products were 
obtained with formaldehyde alone. Molecular 
weights by mass spectrometry and NMR studies (1H 
and 13C) revealed that the less soluble product had 
the expected symmetrical structure 71 while the 
more soluble one had the more complex architecture 
depicted in 72. The formation of 72 was explained 
by postulating the formation of an intermeda  aza-
diene 70 two units of which undergo a hetero Diels–
Alder Reaction (scheme 16).  
5.3 Villsmeyer–Haack (VH) reaction products from 
1-methyl-3,4-dihydroisoquinolines 
1-Methyl-3,4-dihydroisoquinolines 73 are known to 
exist in equilibrium with the enamines 74 which can 
be attacked by electrophiles at the carbon terminus. 
An ambitious plan was initiated by P J Rodriguez (a 
PhD scholar in the Searle Laboratories – Searle was 
r cognised by Bombay University as Cib  also was 
but I was leaving Ciba by the time the recognition 
was granted) to carry out a VH reaction on 73, and 
to subject the carboxaldehyde 75 so produced to 
conditions of the Hantsch dihydropyridine synthesis 
to enter into the azaberberine system 76 present in 
th  Alangium alkaloids as shown in scheme 17. The 
objective was only partly reaized but some unusual 
transformations occurred which are worth recording. 
 VH reaction of 3,4-dihydro-6,7-dimethoxy-1-
methylisoquinoline 77 with 5 molar equivalents ach 
of POCl3 and DMF at 28°C gives the expected for-
myl drivative 78 as the major product. With 2 equi-
valents of POCl3 and 5 of DMF at 80–9 °, 77 gives 
preponderantly the diformyl product 79. The forma-
tion of products like 78 and 79 are general reactions 
of 73 (scheme 18).  
 Various attempts to perform a Hantsch reaction 
with 78 failed. When subjected to same reaction, 79 
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does not yield the desired azaberberine system but a 
product identified as 80 is obtained. Under the opti-
mistic belief that blocking the nitrogen atom by an 
acyl group, thus strengthening the carbonyl character
of the formyl group may direct the reaction suitably, 
79 was allowed to react with acetic anhydride. The 
product however was the unexpected oxadiazozine 
81 (scheme 19). Analytical and spectral data as well 
as single-crystal X-ray studies by Dr R Parthasara-
thy were provided in favour of 81.59 This again is a 
general reaction of the analogues of 79. 
 While this was gratifying per se, more exciting 
was the outcome of the VH reaction on 77 with 5 
moles each of DMF and POCl3 at 80–90°, which re-
sults in the formation in good yield of a product car-
rying two dimethylamino gr ups. The structure was 
deduced to be 82 by analytical and spectroscopic 
measurements and was confirmed by single-crystal 
X-ray studies by Dr Nethaji. The unusual reaction is 
again a general one for dihydroisoquinolines 73 and 
was rationalized.60,61 
 
MeO
MeO N NMe2
NMe2OHC
82  
6. Natural products chemistry 
I had seven years of experience in this field from my 
association with Prof T R Govindachari and for one 
year with Prof H Schmid. Neverthel ss at the start of
 
 
 
 
 
 
 
 
 
 
 
 
 
 
independent professional career I switched over to 
synthetic medicinal chemistry by destiny rather than 
desire. However, the interest persisted and there 
were ample opportunities to work with Prof Govin-
dachari at Ciba and Prof B R Pai at Presidency Col-
lege, Madras on structural elucidation of natural 
products as well as synthesis. 
6.1 Ishwarone 83 and ancistrocladine 84 
The structure of ishwarone, a carryover from Mad as 
was established as 83 by degradation as well as using 
high field NMR data with decoupling studies62,63 
(scheme 19). Ancistrocladine, isolated from Ancy-
strocladus heyneanus at Ciba, was shown to have 
the novel polyketide derived isoquinoline structure 
8464 (scheme 19). Both 83 and 84 are prototypes of 
their scaffolds. Dr P C Parthasarathy was the lead 
chemist in these investigations. I also played a small 
role in the elucidation of the absolute configuration of 
cantharic acid and palasonine by Prof H Schmid.65 
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6.2 Protoberberine chemistry 
Association with Prof Pai in work on protoberberine 
alkaloids was very productive66 and resulted in sev-
eral publications – tructure of neooxyberberineace-
tone,67 synthesis of 13-methylprotoberberines and 
their conformation68 etc. The unexpected formation 
of the fragment CH2 O2H in the mass spectrum of 
neooxyberberineacetone called for some explanation 
which was provided with the help of Dr W J Rich-
ter.67 Two exercises resulted in much excitem nt and 
would bear discussion. 
 An attempt was made to construct a 13-methyl-
tetrahydroberberine 86 from the 1-(a-methylben-
zyl)-1,2,3,4-tetrahydroisoquinoline 85 with formal-
dehyde under acid catalysis. The product is not the 
prosaic target 86 but one of profound rearrangement, 
the isoquinobenzoxazepine 8768 (scheme 20). The 
structure was deduced from analytical/spectroscopic 
data and degradation studies and confirmed by X-
ray.69 
 A second interesting observation was made during 
photolytic debenzylation or exposure to acidic con-
ditions of 1-benzyltetrahydroisoquinolines such as 
88 carrying methoxy groups in the aromatic rings. 
Apart from the expected products, tetrahydroproto-
berberines 89 (scheme 21) are also isolated as signi-
ficant byproducts. Careful experimentation revealed 
that formaldehyde implicated in the side reaction 
arises from the CH2N  moiety under photolytic and 
the aromatic methoxyl under acidic conditions.70 
There was also a three-way collaboration with Prof 
T Kametani of Japan in synthetic work on protober-
berines and aporphines.71 
6.3 Azaberberines and ring B, C isomers 
Mention was made earlier of the unsuccessful at-
tempts to build the azaberberine framework 76 of 
Alangium alkaloids but even if they had been success-
ful, the product would have undesired encumbra es 
which are inevitable from the synthetic route cho-
sen. In a different classical approach, the naturally 
occurring alkaloid 92 could be obtained from 3,4-
dihydroisoquinoline 90 and 4-chloromethylnicotinoyl 
chloride 91. Interestingly apart from the targeted 
azaberberinone 92, the novel pyridopyrroloben-
zazepinone 93 is also obtained and charaterized by 
analytical and spectroscopic data (scheme 22). Addi-
tionally single crystal X-ray studies carried out by 
Prof Nethaji confirmed the structure. Compounds 
corresponding to 92 and 93 with methylenedioxy 
and trimethoxy groups were obtained from the cor-
responding dihydroisoquinolines. Although 93 and 
anal gues have not been isolated so far from plants, 
there is reason to believe that they may be produced 
biogenetically in Alangium lamarcki by rearrange-
ment of 92 and its congeners through a transform-
tion with precedence in protobeberine chemistry.72 
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7. Studies on NMR spectroscopy 
My exposure to this field during postdoctoral asso-
ciation with Prof J D Roberts at Caltech has left an 
indelible lifelong imprint on my activities. Highly 
successful applications of NMR spectroscopy were 
made in association with Prof H Schmid and Dr W 
von Philipsborn at Zurich University in the structural 
elucidation of the Kopsia alkaloids and their rear-
rangement products. 
 For quite a few years after work started at the 
Ciba Research Centre, a Varian A-60 proton NMR 
spectrometer was the ‘owner’s pride and neigh-
bour’s envy’! Much later a low resolution mass 
spectrometer and a 90 MHz Bruker 1H/13C NMR 
spectrometer were added to strengthen the Centre’s 
capabilities. Compared to the facilities available in 
most academic and industrial laboratories today, this 
instrumentation would look primitive but quite a 
good mileage could be obtained from them. In colla-
boration with Dr S Rajappa, extensive studies were 
made in the proton73 and 13C NMR74 spectra of 
enamines and nitroenamines correlating chemical 
shifts with reactivity. 
 Restricted rotation of the amide bond in N-acyli -
dolines and tetrahydroisoquinolines was investigated 
in association with Dr M D Nair75–77 and Prof G 
Kartha.78 This resulted in the discovery of allylic
A(1,3) interactions in some of the molecules and the 
synthesis of strained tetracyclic pyridophenanthridi-
nes.79 
 The rest of this section will highlight selected NMR 
studies related to bi active heterocycles. 
7.1 Applications of 13C NMR spectroscopy to 
structure elucidation of bioactive heterocycles 
Thiazole derivatives: Thiazoles show a variety of 
biological activities, e.g. thiamine, a vitamin with the 
thiazolium moiety. Among other examples can be 
mentioned nizatidine (antiulcer), niridazole (antipro-
tozoal) and thiabendazole (anthelminthic). Among 
reduced thiazole derivatives can be cited the diu-
retic, etozoline, which is a thiazolidinylidene acetic 
acid. A particularly facile and versatile route to thia-
zolidinones, which was the rage in the 1960s and 
70s, is the addition of acetylene dicarboxylic ester 
94 to thiocarbamoyl derivatives 95. Considerable 
controversy surrounded the assignment of structures 
to these products. The possibilities were enormous 
and different structures were proposed by various 
groups. My collaboration with Prof W von Philips-
born allowed an unequivocal and unique solution to 
the vexatious isue. Study of chemical shifts and 
coupling constants in the 13C NMR spectra of a large 
number of these adducts established unambiguously 
the E-thiazolidinone structure 96, ruling out many 
other alternatives such as imidazoline and thiazine 
representations 97 and 98 respectively (scheme 23). 
Crucial to the solution was the identification of the 
carbon atoms of the ester and lactam C=O groups 
and the 3 J  C–H coupling of the latter with the viny-
lic proton (both starred). The method also helped 
structural assignments in the case of most unsy-
metrical thioureas.80 Single crystal X-ray studies on 
the product from N-(4-bromophenyl)-N¢-methylthio-
urea by G Kartha81 confirmed such structures. The 
study was extended to several other addition produ-
cts of 94.82 
 
Imidazoles and pyrazoles: The three-bond C–H 
coupling helped correct assignment of structures to 
isomeric 4- and 5-nitroimidazoles 99 and 10083 and 
to isomeric pyrazoles 101 and 10284 (scheme 24). 
The starred carbon atoms in 99–102 are easily iden-
tified by the large one-bond C, H coupling. Of these 
four structures, those in 99 and 101 have an addi-
tional three-bond C, H coupling which is strikingly 
absent in 100 and 102. Additionally, there are diag-
nostic differences in the chemical shifts between the 
starred carbons in 99 and 101 and between 101 and 
102. It should be mentioned that 5-nitroimidazoles 
100 a e potent antiprotozoals (e.g. satranidazole 18), 
while the 4-nitroisomers 99 are devoid of this acti-
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vity, although in bicyclic molecules incorporating 
99, such as the imidazooxazole CGI 17341, 30, potent 
antitubercular activity has been discovered, which is 
absent in the 5-nitroisomer.41 
 Compounds 101 and 102, with R = arylpiperazines, 
are potent antihypertensives.84 Significant results 
were also obtained in collaboration with Prof Von 
Philipsborn in the 15N spectra of azoles containing 
two hetero atoms.85 
8. Contributions to process development 
The change from basic research of the type carried 
out at Ciba to applied research at Searle in Bombay 
and later at Recon and now at Hik l in Bangalore 
provided different types of challenges with fruitful 
results. Process development of quinfamide 27 by 
Sharada Shenoy and manufacture at Searle India was 
mentioned earlier. An equally satisfactory experi nce 
was the elaboration of a commercially viable route 
to the life-saving purine immunosuppressant, aza-
thioprine 103 by Dr Shenoy and commercialization 
by Searle which brought her the coveted Vasvik 
Award for lady scientists in 1990. Process develop-
ment of drugs again has been the major thrust at Re-
con and Hikal and has resulted in the production of a 
large number of drugs of varying complexity. 
 
N
N
N
N
N
H
N
S
NO2
Me
103  
 
 Searle India, uniquely among G D Searle’s outfits, 
was also involved in process development of pesti-
cides in those days due to the peculiar economic 
compulsions of the MNC industry in India. This gave 
me good exposure to this chemistry, which has sig-
nificant similarities to medicinal chemistry. Among 
many known pesticide molecules for which pro-
cesses were developed at Searle, mention may be 
ade of butachlor, a herbicide, diflubenzuron 105, a 
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chitin synthesis inhibitor, fluocythrinate and MTI 
500 (107) (scheme 25), the last two insecticides be-
longing to the synthetic pyrethroid group. A simple 
viable route was develop d by Dr K R Ramachan-
dran for 105 which was patented in India, involving 
synthesis of the corresponding acylthiourea 104 and 
replacement of sulphur by oxygen. A synthesis of 
MTI 500 (107) was also achieved wherein the thio-
ester 106 was desulphurised! The lead chemist for 
this patented route was Dr T V Radhakrishnan. 
9. Current interests 
9.1 Binding sites of active drugs 
In recent years, I have been collaborating more i-
tensely with X-ray crystallographers and biophysi-
cists in studies involving binding sites of bioactive 
molecules and supramolecular interactions in the solid 
state. For this purpose I can draw upon a library of 
about 2000 compounds I had prepared at Ciba Re-
search Centre and carry out a limi ed amount of new 
chemistry with minimal human and material resou-
ces available for new rsearch in laboratories largely 
devoted to process development. 
9.2 Studies on bioactive molecules 
During nearly a decade of association with Prof 
Vasantha Pattabhi, crystal structures of the hypogly-
cemic perhydroindoles 60 (Go8778, R= Me, R1 = n-
Bu)86 and (Go 9001, R = Me, R1 = iso-Bu)
87 and 65 
(CGI 14600, R= Ph) and its active and inactive ana-
logues were studied and attempts made to map puta-
tive binding sites by overlaying them on the stru-
ctures of tolbutamide and glibenclamide.88 
 Polymorphism (or its absence) of the antiamoebic 
drug, satranidazole 18, was the focus of another in-
vestigation.89 An interesting sequel to this publication 
was an invitation to submit several nitroimidazoles  
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Scheme 25. 
synthesized by me for screening against leishmani-
a is and trypanasomiasis by the not-for-pr fit orga-
nization, Drugs for Neglected Diseases. 
 Interesting papers were published on anti-inflam-
matory agents, which act by inhibition of cyclooxy-
genase. This enzyme is known to exist in two 
isoforms, COX 1 and COX 2. The former is a con-
stitutive enzyme and has the housekeeping task of 
cytoprotection. The latter is generated at the site of 
injury and induces the synthesis of proinflammatory 
prostaglandins. Selective or specific inhibitors of 
COX-2 may be expected to provide relief without 
production of ulcers. Nimesulide 108 and meloxicam 
109 (scheme 26) belong to the class of selectiv  
COX 2 inhibitors. Their crystal structures were elu-
cidated and the drugs docked in the known active 
sites of COX 1 and COX 2 proteins. Binding, desta-
bilizing and intermolecular energies were then de-
rived. The values clearly showed that 108and 109 
bound COX 2 better than COX 1, thus presenting a 
theoretical explanation for the observed selectivity. 
Modifications to the structure of meloxicam 109 were
proposed to enhance the selectivity.90–92 
 In a collaborative project with Prof P Balaram, the 
conformations of the aminomethyl and carboxy-
methyl side chains in gabapentin 110, a blockbuster 
anticonvulsant and several relatives were delineat d 
using X-ray crystal studies and high field 1H NMR 
investigations at various temperatures.93 To under-
stand the conformation in which the aminomethyl 
group in 110 binds to a receptor, analogues 111 and 
112 (scheme 27), with the classical t-butyl anchoring 
group have been made. 
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9.3 Supramolecular interactions 
Sustained collaboration with Prof T N Guru Row 
started with a chance remark by the latter that he 
was looking for biologically interesting fluorine-
containing organic molecules to study possible F,F 
interactions in the solid state. I could provide him a 
number of samples with the templates in 33, 38, 47 
and 50. Out of several struc ures solved, uniquely 38 
showed appreciable intermolecular F–F inter-
action.94–96 The availability of old analogues and 
synthesis of newer ones made it possible to have 
structure-substituent analysis.97,98 After initial skep-
ticism, F–F interactions are slowly but steadily r-
ceiving international acceptance. The occurr nce of 
F–F interactions and their nature have been put on a 
firm foundation by Guru Rao and Chopra, based on 
charge density calcultions on an analogue of 47 
with an additional methyl group at position 3 on the 
indole which displays two polymorphic modificati ns, 
one of them showing the intriguing F–F interaction. 
9.4 Cyclbutadiene chemistry revisited – A parting 
shot 
It is only appropriate to end this review with inter-
esting results which unfolded when I revisited the 
cyclobutadiene chemistry I had carried out in 1959–
1960 with Prof J D Roberts at Caltech. This was in-
spired by the availability of samples with him even 
after the lapse of 45 years and Prof Guru Row’s in-
terest in the crystal structures of fluoroorganics and 
the X-ray crystallographic facilities available to him 
at IISc, which enabled rapid solutions of crystal 
structures (provided suitable crystals can be made). 
Available samples from the cyclobutadiene chemistry
were obtained from Caltech and subjected to inves-
tigation. Mass and high field NMR data inaccessible 
in 1959–1960 were gathered and a number of reac-
tions run or rerun. The fascinating conclusions are 
presented below. 
 In 1959, the reaction of cyclobutene 113 with ex-
cess phenyl lithium had been studied with the hope 
that this would lead to the heavily loaded triphenyl-
fluorocyclobutadiene 114. However, the major 
product obtained in moderate yield was a white 
dimer C44H30F2 whose structure was deduced to be 
115 on the basis of analytical and spectroscopic, 
particularly Raman data and also interesti gly by 
dipole moment measurement.13 The structure was 
confirmed by X-ray studies details of which were 
not fully published.99 A minor sparingly soluble pro-
duct A having the molecular composition C44H29F 
has now been shown to be the fluoropentaphenyl-
phenanthrene 117, probably arising from a dimer 
116 similar to 115 but with different dispositions of 
phenyl groups and the fluorine atom, by the loss of 
elements of hydrogen fluoride. The dimer 115 also 
loses the elements of HF upon short boiling in decalin 
to afford a sparingly soluble, high melting product B 
which is considered to be the phenanthr e 118. The  
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major product of this reaction is a yellow compound 
C which is solely obtained upon sh rt heating of 
115 at its melting point. The product having the 
same molecular formula as 115 was originally assig-
ned the dihydropentalene structure 119 but has been 
now found to be 120. The structure of the orange keton
D obtained from C by sulphuric acid hydrolysis, 
originally considered to be 121, has been ow cor-
rected as 122. Finally, the photolysis product of 115, 
a yellow ketone isomeric with D has been found in 
fact to have the structure 121 (scheme 28). Plausible 
explanations for the deep-s ated rearr ngements and 
transformations encoutered in this study have been 
proposed.100 Of course Prof. Guru Row was not too 
happy with the crystal structures since they all show 
only CH-f interactions and no H–F contacts, not to 
speak of F–  associations!  
10. Conclusion 
I have tried to show that interesting rsearch can be 
carried out within the constraints of industrial re-
quirements, which can offer great challenges and 
provide ample excitement. 
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